Denny Lanfear

Mr. Denny Lanfear is a member of the Board of Directors at NEUVOGEN. He serves as Chairman, President, and Chief Executive Officer of Coherus BioSciences, the world’s largest biosimilar company. He is a biosimilar pioneer and biopharmaceutical leader with a proven track record of successful entrepreneurial vision and achievement. In 2010, after decades working in the biopharmaceutical industry, Mr. Lanfear founded Coherus BioSciences with the vision of improving the public’s access to high-quality, life-changing medicines. Under his leadership, Coherus BioSciences was transformed from an unfunded startup into the industry’s leading pure play biosimilar company, with over $1.25 billion in funding being raised since its inception. Coherus has experienced outstanding success with the launch of its first drug, UDENYCA® (pegfilgrastim-cbqv). A dedicated entrepreneur, Mr. Lanfear founded and served as CEO at two other companies before Coherus: Saronyx, Inc., a drug development software services company, and the biopharmaceutical company InteKrin Therapeutics. Mr. Lanfear has held various senior leadership roles at Amgen Inc., serving as Vice President of Process Development and Vice President of Market Development. During his 13-year tenure at Amgen he also acquired substantial operations experience, and was tasked with integrating more than 2,500 operations and staff worldwide after the company’s explosive growth. Mr. Lanfear’s product development experience includes various leadership positions with multiple product development programs including growth factors, somatotrophins, and neurotrophins, having directed efforts from preclinical studies to Phase 3 clinical trials. Mr. Lanfear holds BS degrees in Chemical Engineering and Biochemistry from Michigan State University and an MBA from the Anderson School of Management at the University of California, Los Angeles.